Lonza, CH0013841017

Lonza Group stock holds steady as investors await fresh catalysts

Published on 07/22/2026 at 07:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Lonza Group stock remains anchored by its latest reported financial base, with 2025 revenue at CHF 6.57 billion and core EBITDA at CHF 1.92 billion.

Fotorealistische Reinraum-Bioreaktor-Halle mit glänzenden Edelstahltanks und steriler LED-Beleuchtung
Lonza CH0013841017 zeigt Reinraum Bioreaktor Halle mit Edelstahl Tanks steriler LED Beleuchtung, Illustration mit AI erstellt.

Lonza Group (CH0013841017) remains anchored by its 2025 financial base, with revenue of CHF 6.57 billion and core EBITDA of CHF 1.92 billion. The company also reported core EBITDA margin of 29.2% for 2025, showing how profitability stayed elevated even as the group reset its operating footprint.

Revenue and margin stay central

Lonza reported 2025 sales of CHF 6.57 billion, up from CHF 6.57 billion in the prior period context used in its annual reporting framework and paired with core EBITDA of CHF 1.92 billion. The 29.2% margin is the key figure investors can compare against Lonza's own profitability history, because it gives more context than revenue alone.

The company also disclosed net debt of CHF 1.31 billion at year-end 2025, a balance sheet metric that matters in a capital-intensive CDMO model. That leverage profile gives a cleaner read on flexibility than earnings headlines alone.

Margins still matter most

For Lonza stock, the more useful question is not whether the business can sell volume, but whether it can preserve margin while it scales. The 2025 numbers show CHF 6.57 billion in revenue, CHF 1.92 billion in core EBITDA, and a 29.2% core EBITDA margin, which together define the operating base.

That mix also sets the comparison frame for later updates: any change in revenue growth, margin, or debt will matter more than broad sector rhetoric. Investors following the shares can use those three figures as the clearest reference points from the latest full-year reporting cycle.

Product exposure stays broad

Lonza's business spans biopharmaceutical manufacturing and related services, so the investment case is tied to throughput, quality, and long-cycle customer demand rather than one consumer product. In practice, the revenue and EBITDA mix is the most relevant proxy for that exposure until a new company update adds fresh detail.

The 2025 annual figures are still the cleanest way to read the group's operating strength because they combine scale, profitability, and balance-sheet discipline in one set of numbers.

Market value frame

The shares are listed in Switzerland on SIX Swiss Exchange, and the stock should be read against that local market backdrop. A current quote was not available in the provided search results, so the latest evidenced valuation frame in this article is the 2025 operating data above.

Lonza Group at a glance

  • Company: Lonza Group AG
  • ISIN: CH0013841017
  • Ticker: SIX: LONN
  • Trading venue: SIX Swiss Exchange
  • Sector / Industry: Health Care / Pharmaceuticals, biotechnology and life sciences
  • Index membership: SMI

Follow Lonza Group coverage

Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.

en | CH0013841017 | LONZA | boerse | 69831819 | bgmi